Q/C Technologies (QCLS) Q3 2024 earnings summary

Executive summary

• Focused on developing MYMD-1 for age-related illnesses and Supera-CBD for neurological conditions, with MYMD-1 advancing based on positive Phase II data and ongoing regulatory preparations.

• No product revenue generated; operations funded primarily through equity and preferred stock offerings.

• Significant cost reductions implemented, including workforce reductions and executive compensation adjustments.

Financial highlights

• Net loss attributable to stockholders was $24.0 million for the nine months ended September 30, 2024, compared to a net loss of $3.3 million for the same period in 2023.

• Cash and marketable securities totaled $10.6 million as of September 30, 2024.

• Working capital was $5.0 million and stockholders' equity was $16.8 million at quarter end.

• Operating expenses decreased year-over-year, with general and administrative expenses down $1.0 million and R&D expenses down $2.6 million.

• No revenue from product sales; all revenue is from investment income.

Outlook and guidance

• Management believes current financial resources are sufficient to fund operations and contractual obligations for at least the next twelve months.

• Ongoing focus on advancing clinical programs and seeking non-dilutive funding opportunities.